• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Provident Financial Services

Related Topics

  1. Scientific Industries
  2. Ocean Energy
  3. First Mariner Bancorp
  4. Capital Gold
  5. Compton Petroleum
  6. Montreal Exchange

Popular Topics

  1. Procter & Gamble
  2. Sears Holdings
  3. Dean Foods
  4. Emerging Markets
  5. Stock Market

Provident Financial Services

Provident Financial Services PFS

Last Price$15.59Day Change (%)0.65%
Open Price$15.45Day Change ($)0.10
Day Range15.33–15.5952-Week Range13.13–16.25

As of Fri 05/24/2013 01:28 PM EDT | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Genentech’s Obinutuzumab (GA101) Significantly Reduced the Risk of Disease Progression or Death in People with One of the Most Common Forms of Blood Cancer

    Genentech’s Obinutuzumab (GA101) Significantly Reduced the Risk of Disease Progression or Death in People with One of the Most Common Forms of Blood Cancer

  2. Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO

    Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO

  3. FDA Approves Tarceva (Erlotinib) Tablets and Cobas EGFR Mutation Test for Specific Type of Lung Cancer

    FDA Approves Tarceva (Erlotinib) Tablets and Cobas EGFR Mutation Test for Specific Type of Lung Cancer

  4. Oncolytics Biotech® Inc. Announces First Quarter 2013 Results

    Oncolytics Biotech® Inc. Announces First Quarter 2013 Results

  5. Active Biotech and Ipsen Update the Analysis Plan for the 10TASQ10 Trial Evaluating Tasquinimod in the Treatment of Prostate Cancer

    Active Biotech and Ipsen Update the Analysis Plan for the 10TASQ10 Trial Evaluating Tasquinimod in the Treatment of Prostate Cancer

  6. Capstone Mining to Purchase Pinto Valley Copper Mine

    Capstone Mining to Purchase Pinto Valley Copper Mine

  7. Ipsen’s First Quarter 2013 Sales

    Ipsen’s First Quarter 2013 Sales

  8. OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer

    OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer

  9. NAPFA’s CFP-Only Stand: A Step in the Wrong Direction

    A curious move, at a curious time, for purportedly, a curious reason, that is also a slap in the face to CPAs with the PFS credential.

  10. Using ETFs in 401(k) Plans

    This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...

123
Our Products
Tools
Resources
Services
Upcoming Events
Conferences
Webinars

©2012 Morningstar Advisor. All right reserved.